Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA-CMS Parallel Reviews: Too Close for Comfort?

This article was originally published in RPM Report

Executive Summary

Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.

You may also be interested in...



Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS

Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.

Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

EPO Market Stabilizes, But For How Long?

Amgen hoped it would be turning the page on the regulatory and reimbursement problems that dogged Aranesp and made 2007 a year to forget. But more negative data means another trip to an FDA advisory committee, and this time Wall Street is bracing for the worst.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel